New Crown Outbreak: 36.8 million cases! Johnson and Johnson and the European Commission reached a COVID-19 vaccine supply agreement: 400 million doses to EU member states!

October 10, 2020 / / -- At present, the outbreak of new crown pneumonia abroad is still spreading rapidly.
according to Baidu's Real-Time Big Data Report on the Outbreak of New Coronavirus Pneumonia, as of 19:00 on October 09, 2020, there were more than 36.8 million confirmed cases and more than 1.06 million deaths worldwide.
vaccine is the ultimate weapon in the fight against neo-pneumonia, and several pharmaceutical companies are actively promoting their own vaccine programs.
, the European Commission, on behalf of European Union member states, has ratified a pre-procurement agreement, the JNJ announced.
the agreement, Johnson and Johnson's Janssen Pharmaceuticals will supply 200 million doses of COVID-19 vaccine to EU member states after the candidate vaccine is approved or authorized by regulators.
EU member states can also choose to receive additional doses of up to 200 million doses.
contract was signed after tentative negotiations with EC.
As part of its commitment to supply vaccines globally, the company is in discussions with other stakeholders, including governments and global organizations, to make vaccines available globally as long as they are safe, effective and approved or authorized by regulators.
In addition to the agreement with the EC, as part of the company's larger commitment to the COVID-19 pandemic, Johnson and Johnson also announced a plan to allocate up to 500 million doses of the vaccine to international efforts to ensure access to vaccines in low-income countries, which will begin delivery in the middle of next year after regulatory approval or authorization.
recognizing the unique global demand for the new crown vaccine, Johnson and Johnson are working to expand the available doses of the vaccine worldwide.
COVID-19 vaccine (Photo: santiagotimes.cl) Johnson and Johnson is developing and testing its Youngson COVID-19 candidate vaccine in accordance with its consistently strict safety ethical standards and sound scientific principles.
the company is evaluating a single-dose immunization programme that launched a large-scale, critical, multi-country Phase 3 clinical trial (ENSEMBLE) in September.
the company plans to begin Phase 2 Phase 3 clinical trials later this year, using a two-dose immune program.
company is committed to transparency and sharing information related to phase 3 ENSEMBLE research, including research programs.
's COVID-19 vaccine uses Jansen's AdVac ® technology.
same technology is also being used to develop Ebola vaccine programmes (approved by the EUROPEAN Union) and are the basis for its HIV, RSV and Zika vaccine candidates.
, more than 100,000 people have been vaccinated against Jansen's AdVac ® vaccine.
based on an understanding of vaccine stability, Johnson and Johnson expects its COVID-19 vaccine to be compatible with standard distribution channels without the need for a new distribution infrastructure.
(s) Origin: Johnson and Johnson Announcs European Commission Of Office to Supply 200 Million Doses of Janssen's COVID-19 Vaccine Candidate.